APA (7th ed.) Citation

Conter, H., MacDonald, L., Fiset, S., Bramhecha, Y., Chaney, M., & Rosu, G. (2019). Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours: Preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts. Annals of oncology, 30, v494. https://doi.org/10.1093/annonc/mdz253.034

Chicago Style (17th ed.) Citation

Conter, H.J, L.D MacDonald, S. Fiset, Y.M Bramhecha, M. Chaney, and G.N Rosu. "Safety and Efficacy Results of the Combination of DPX-Survivac, Pembrolizumab and Intermittent Low Dose Cyclophosphamide (CPA) in Subjects with Advanced and Metastatic Solid Tumours: Preliminary Results from the Hepatocellular Carcinoma (HCC), NSCLC, Bladder Cancer, & MSI-H Cohorts." Annals of Oncology 30 (2019): v494. https://doi.org/10.1093/annonc/mdz253.034.

MLA (9th ed.) Citation

Conter, H.J, et al. "Safety and Efficacy Results of the Combination of DPX-Survivac, Pembrolizumab and Intermittent Low Dose Cyclophosphamide (CPA) in Subjects with Advanced and Metastatic Solid Tumours: Preliminary Results from the Hepatocellular Carcinoma (HCC), NSCLC, Bladder Cancer, & MSI-H Cohorts." Annals of Oncology, vol. 30, 2019, p. v494, https://doi.org/10.1093/annonc/mdz253.034.